Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 10/20 | 0.58 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.39 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13104782 | 0.86 | DRD3 (0.59) | DRD3CNR2 | |
| SCHEMBL28305281 | 0.84 | DRD3 (0.58) | DRD3CNR2MGAT2MOGAT2 | |
| SCHEMBL4208273 | 0.84 | DRD3 (0.58) | DRD3CNR2MGAT2MOGAT2 | |
| SCHEMBL2295959 | 0.84 | DRD3 (0.58) | DRD3CNR2MGAT2MOGAT2 | |
| SCHEMBL2293451 | 0.84 | DRD3 (0.58) | DRD3CNR2 | |
| SCHEMBL2298686 | 0.84 | DRD3 (0.58) | DRD3CNR2MGAT2MOGAT2 | |
| SCHEMBL2294607 | 0.84 | DRD3 (0.58) | DRD3CNR2MGAT2MOGAT2 | |
| SCHEMBL2296989 | 0.84 | DRD3 (0.58) | DRD3CNR2MGAT2MOGAT2 | |
| SCHEMBL2297490 | 0.84 | DRD3 (0.58) | DRD3CNR2 | |
| SCHEMBL12387532 | 0.84 | DRD3 (0.69) | DRD3CNR2MOGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008026046-A1 | MORPHOLINE D3 DOPAMINE ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-03-06 | — | — | WO | claimed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2008026046-A1 | MORPHOLINE D3 DOPAMINE ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008026046-A1 | MORPHOLINE D3 DOPAMINE ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | DRD3 3026/4885CNR2 1852/4885KDM4E 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.